BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35748298)

  • 1. Cost-effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China.
    Zhang X; Fang P; Su G; Gui S; Shen A
    J Comp Eff Res; 2022 Aug; 11(12):871-878. PubMed ID: 35748298
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
    Li H; Lai L; Wu B
    Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
    Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
    J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
    [No Abstract]   [Full Text] [Related]  

  • 5. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
    JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
    Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
    Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
    Guan H; Sheng Y; Guo W; Han S; Shi L
    Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
    Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
    Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
    Carlson JJ; Suh K; Orfanos P; Wong W
    Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
    Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
    Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
    Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
    J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China.
    Huang M; Tian Y; He M; Liu J; Ren L; Gong Y; Peng F; Wang Y; Ding Z; Wang J; Zhu J; Xu Y; Liu Y; Li L; Lu Y
    J Comp Eff Res; 2020 Jan; 9(2):93-102. PubMed ID: 31958984
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    Lu S; Yu Y; Fu S; Ren H
    PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.
    Zhang M; Zheng B; Yang W; Jiang H; Sun X; Zhao Z; Li G; Dong H
    Clin Med Insights Oncol; 2024; 18():11795549241257234. PubMed ID: 38827520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Chan CPK; Chang A; Zhou ZY; Xie J; Gibbs M
    Cost Eff Resour Alloc; 2020 Nov; 18(1):50. PubMed ID: 33292314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
    Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
    Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ; Canestaro W; Ravelo A; Wong W
    J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
    Singhi EK; Horn L
    Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer].
    Zhang L; Yang YP; ;
    Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):297-307. PubMed ID: 35448917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.